Comment
doi: 10.1016/j.jtho.2023.08.013.
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial"
Affiliations
- PMID: 38185511
- DOI: 10.1016/j.jtho.2023.08.013
Item in Clipboard
Comment
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial"
J Thorac Oncol.
2024 Jan.
Free article
No abstract available
Comment in
-
Response to Letter to the Editor From Shaorong Yu and Jifeng Feng.J Thorac Oncol. 2024 Jan;19(1):174-175. doi: 10.1016/j.jtho.2023.10.018. J Thorac Oncol. 2024. PMID: 38185512 No abstract available.
Comment on
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. Epub 2022 Aug 9. J Thorac Oncol. 2022. PMID: 35961520 Clinical Trial.
Similar articles
-
Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial.J Thorac Oncol. 2023 Jan;18(1):e1-e2. doi: 10.1016/j.jtho.2022.09.002. J Thorac Oncol. 2023. PMID: 36543435 No abstract available.
-
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18. Future Oncol. 2024. PMID: 39023287 Free PMC article.
-
DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.Future Oncol. 2021 Dec;17(34):4657-4663. doi: 10.2217/fon-2021-0952. Epub 2021 Nov 15. Future Oncol. 2021. PMID: 34775804
-
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319991 Review.
-
The role of chemoradiotherapy and immunotherapy in stage III NSCLC.Pathol Oncol Res. 2024 Apr 19;30:1611716. doi: 10.3389/pore.2024.1611716. eCollection 2024. Pathol Oncol Res. 2024. PMID: 38706775 Free PMC article. Review.
Cited by
-
Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).Cancers (Basel). 2025 Apr 25;17(9):1443. doi: 10.3390/cancers17091443. Cancers (Basel). 2025. PMID: 40361370 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
